Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

Insiders have been trading these 5 stocks: (($CAVA)), (($AAOI)), (($ELV)), (($INOD)) and (($ABAT)). Here is a breakdown of their recent trades and ...

CAVA, Applied Optoelectronics, Elevance, Innodata, American Battery Shock

An announcement from Innodata ( ($INOD) ) is now available. On June 17, 2026, Innodata Inc. (Nasdaq: INOD), a global data engineering company that ...

Innodata Appoints New CFO to Drive AI Growth

Innodata ( ($INOD) ) has provided an announcement. Innodata Inc. held its Annual Meeting of Stockholders on June 4, 2026, where shareholders electe...

Innodata Shareholders Back Directors, Auditor and Pay Plan

Wedbush Securities analyst Daniel Ives has declared Claude Code maker Anthropic the world’s top artificial intelligence (AI) model, leaving no riva...

Market Cap	$112.66M	P/E Ratio	N/A
52W High	$2.98	52W Low	$1.03
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	49.5%	52W Position	4.4%
Overall Score	37	Value Score	--
Quality Score	34	Technical Score	40

EPS Current Est	$-0.97	EPS Next Est	$-0.41
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$1.12	0.00%	337.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$1.12	0%	337.59K
3
4
5
6

INO

INO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel